New Zealand markets open in 2 hours 44 minutes

Merck KGaA (MKGAF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
165.000.00 (0.00%)
At close: 03:46PM EDT

Merck KGaA

Frankfurter Strasse 250
Darmstadt 64293
Germany
49 6151 72 0
https://www.emdgroup.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full-time employees62,345

Key executives

NameTitlePayExercisedYear born
Ms. Belen Garijo Lopez M.D.Chair of Executive Board & CEO7.23MN/A1960
Ms. Helene von RoederCFO & Member of Executive Board1.35MN/A1970
Dr. Kai BeckmannCEO of Electronics & Member of the Executive Board5.3MN/A1965
Mr. Peter GuenterCEO of Healthcare Business & Member of Executive Board6.09MN/A1962
Dr. Matthias J. HeinzelCEO of Life Science Sector & Member of Executive Board5.7MN/A1967
Ms. Barbara WeilandChief Compliance OfficerN/AN/A1974
Mr. Dietmar EidensHead of the Global HR Business Partner OrganizationN/AN/A1958
Mr. Frank GotthardtHead of Corporate & Government Relations - EuropeN/AN/AN/A
Mr. Marc HornHead of Life Science ControllingN/AN/A1975
Dr. Michael HeckmeierHead of the Display Materials Business Unit for Performance MaterialsN/AN/A1967
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Corporate governance

Merck KGaA’s ISS governance QualityScore as of 1 July 2024 is 3. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 10; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.